Key Insights• According to the research report, "USA Diabetes Care Devices Market Outlook, 2031," published by Actual Market Research, the USA Diabetes Care Devices Market was valued at more than 14.73 Billion in 2025.• The US diabetes care market is undergoing a structural paradigm shift as Continuous Glucose Monitoring (CGM) systems displace traditional self-monitoring blood glucose (SMBG) meters. The driver behind this transition is expanded coverage from Medicare Part B and commercial insurers for both Type 1 and non-insulin-treated or basal-only Type 2 diabetes patients. Recent major technological breakthroughs include extended-wear sensors, such as 15-day real-time CGMs (e.g., Dexcom G7 15-day system) and fully implantable sensors that last up to 180 days. Additionally, the emergence of FDA-designated over-the-counter (OTC) glucose monitors such as Dexcom's Stelo and Abbott's Lingo has expanded sensor access to non-insulin Type 2 diabetics, prediabetics, and health-conscious consumers without requiring a prescription.• The market is rapidly advancing toward fully automated closed-loop ecosystem adoption. Breakthroughs in AID systems such as the FDA-cleared Omnipod 5, Tandem Control-IQ, and Medtronic MiniMed 780G utilize advanced algorithms to dynamically communicate with real-time CGMs, adjusting basal insulin automatically to protect patients against severe hypoglycemia and hyperglycemia. Further pushing the innovation frontier, next-generation developments include Phase 1 clinical milestones for fully implantable insulin pump systems (such as the Portal Pump designated as an FDA Breakthrough Device) paired with temperature-stable insulin formulations, moving closer to a functional automated cure for insulin-dependent diabetes.• Data from the Centers for Disease Control and Prevention (CDC) and the American Diabetes Association (ADA) indicate that over 40 million Americans (approximately 12% of the total US population) are living with diabetes.

Among these, roughly 29.1 million have been formally diagnosed, while 11 million remain undiagnosed, alongside an estimated 115 million adults living with prediabetes. Type 1 diabetes affects over 2 million individuals in the US, including more than 314,000 children and adolescents. The direct medical expenditure associated with diagnosed diabetes in the United States exceeds $306.6 billion annually, with total economic costs reaching $412.9 billion. On average, medical costs for individuals diagnosed with diabetes are 2.6 times higher than for those without the condition, driving high demand for remote patient monitoring tools and digital health integrations that mitigate costly hospital readmissions.Market Outlook• The prospective landscape for diabetes devices in the United States is increasingly focused on non-prescription wearables and digital health platform convergence. As the OTC biosensor ecosystem expands beyond core Type 1 populations into the broader Type 2 and prediabetes markets, device manufacturers are heavily investing in AI-driven predictive analytics, mobile app ecosystems, and integrated remote patient monitoring platforms. Future product roadmaps emphasize reduced sensor footprints, needle-free or non-invasive optical/RF glucose sensors, and smart insulin pen integration (such as connected caps and reusable smart injectors) to optimize time-in-range (TIR) metrics and streamline patient data sharing directly into Electronic Health Record (EHR) networks.• While value-based care models and favorable Medicare coverage guidelines are fueling sustained device uptake, market growth faces ongoing friction from out-of-pocket patient costs, restrictive regional insurance formularies, and supply-chain sustainability pressures regarding single-use plastics.

Key regulatory and research organizations guiding policy standards, device approvals, and patient support frameworks include the U.S. Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), the American Diabetes Association (ADA), and the Juvenile Diabetes Research Foundation (JDRF). Leading commercial companies driving market hardware and digital ecosystems include Abbott Laboratories, Dexcom, Inc., Insulet Corporation, Medtronic plc, Tandem Diabetes Care, Senseonics Holdings, and Ascensia Diabetes Care.Market DynamicsDriver: Paradigm shift in insurance reimbursement and clinical indications The primary growth driver for the US diabetes care devices market is the expansion of private and public insurance coverage most notably through Medicare Policy Updates by the Centers for Medicare & Medicaid Services (CMS). Historic eligibility criteria strictly required patients to perform multiple daily insulin injections (MDI) or use an insulin pump to qualify for Continuous Glucose Monitoring (CGM) coverage. Modern coverage guidelines have broadened coverage to include non-insulin-treated Type 2 diabetes patients with documented recurrent or severe hypoglycemia, as well as individuals receiving basal-only insulin therapy.Challenge: Cost barriers, high out-of-pocket expenses, and disparities in access Despite regulatory progress and expanding coverage policies, high out-of-pocket costs, complex health insurance tiering, and socioeconomic disparities represent a major market hurdle. Advanced technologies such as continuous sensors, smart transmitters, automated pumps, and algorithm-driven closed-loop systems require ongoing recurring purchases of disposables (e.g., sensors, infusion sets, cartridges) that accumulate significant long-term expenses.

Patients covered by high-deductible health plans (HDHPs) or those navigating complex prior authorization workflows frequently experience high cost-sharing duties or coverage denials.Trend: Rise of over-the-counter (OTC) biosensors and non-insulin digital health expansion A major trend transforming the market landscape is the transition of continuous glucose monitors from specialized prescription-only medical equipment into accessible consumer-facing biosensors and over-the-counter (OTC) wearables. Following key clearance pathways by the US FDA for OTC continuous monitors, device manufacturers are rapidly expanding their target demographics beyond traditional Type 1 and intensive-insulin Type 2 populations. The market is now actively capturing non-insulin-treated Type 2 diabetics, prediabetic individuals, and lifestyle/wellness-focused consumers seeking real-time metabolic feedback.Policies • Class II Medical Devices (510(k) Clearance): Applied to most Blood Glucose Monitoring (BGM) systems, factory-calibrated integrated CGMs (iCGM), smart insulin pens, and non-adjunctive monitoring systems under 21 CFR Part 862.• Class III Medical Devices (Premarket Approval - PMA): Required for complex or higher-risk devices, such as fully implantable continuous glucose sensors and high-risk automated closed-loop artificial pancreas systems.• Interoperability Standards (iCGM & Alternate Controller Enabled - ACE Pumps): FDA guidelines allowing modular device interoperability, enabling compatible CGMs, algorithms, and pumps from different vendors to pair safely. • 21 CFR Part 820 (Quality System Regulation / QSR): Enforces strict requirements for device design controls, risk management (ISO 14971), supply chain traceability, and manufacturing process validation.• Cybersecurity and Data Protection: Strict FDA premarket cybersecurity requirements for connected, wireless, and mobile-app-enabled medical devices, alongside compliance with HIPAA (Health Insurance Portability and Accountability Act) to safeguard patient Personal Health Information (PHI).• HCPCS Coding & PDAC Verification: Devices must be reviewed by the Pricing, Data Analysis, and Coding (PDAC) contractor to obtain Healthcare Common Procedure Coding System (HCPCS) codes for durable medical equipment (DME) billing. • Local Coverage Determinations (LCDs): Specific clinical documentation compliance monitored by Medicare Administrative Contractors (MACs) to prove medical necessity for ongoing device and supply coverage.Segment AnalysisUSA Diabetes Care Devices By Product Type• The US blood glucose monitoring systems market is shaped by the growing preference for personalized diabetes management, continuous visibility into glucose patterns, and simpler monitoring routines. Traditional blood glucose meters remain relevant for confirmation testing, backup monitoring, and users who prefer straightforward devices, while continuous glucose monitoring systems are changing how patients and healthcare professionals interpret glucose fluctuations throughout the day. Product differentiation increasingly centers on sensor comfort, ease of application, mobile app integration, data sharing with clinicians, and compatibility with digital health platforms. Device manufacturers must also address insurance coverage, affordability, training requirements, and the usability needs of older adults and people with limited digital literacy.

Integration of glucose information with insulin delivery technologies is strengthening the role of monitoring systems in connected diabetes care.• The US insulin delivery devices market is evolving toward more personalized, convenient, and automated insulin administration, with product preferences influenced by treatment complexity, lifestyle, dexterity, and patient confidence. Insulin pens remain attractive for their portability and relatively simple operation, while insulin pumps appeal to users seeking flexible dosing and more consistent integration with glucose monitoring. Automated insulin delivery systems are advancing the shift toward connected care by using glucose sensor information to help adjust insulin delivery, reducing the burden of frequent manual decisions for eligible users. Important competitive factors include discreet device design, infusion-set reliability, ease of training, software usability, and interoperability across monitoring and dosing platforms. Manufacturers also need to consider reimbursement restrictions, ongoing consumable requirements, and the transition from clinician-supervised initiation to confident everyday use. USA Diabetes Care Devices By Disease Type• The US type 1 diabetes care devices segment is characterized by a strong need for dependable, continuous monitoring and precise insulin replacement, making interoperability between glucose sensors and insulin delivery devices especially important. Users often rely on technology throughout the day and night, so device performance during sleep, exercise, meals, and unexpected glucose changes is a major consideration.

Automated insulin delivery, predictive alerts, remote caregiver monitoring, and child-friendly wearable designs are important areas of product differentiation. Device selection also depends on school and workplace routines, sports participation, skin sensitivity, and the ability of families to manage alarms and technical issues. For manufacturers, long-term customer support, training, dependable consumable supply, and compatibility across connected devices are essential to maintaining user confidence and treatment continuity.• The US type 2 diabetes care devices segment serves a broad and clinically diverse population, ranging from individuals managing the condition through lifestyle changes and oral medications to those requiring intensive insulin therapy. This diversity creates demand for flexible monitoring options rather than a single device approach for every patient. Continuous glucose monitoring is increasingly relevant for understanding how meals, physical activity, medication timing, stress, and sleep affect glucose patterns, including for selected patients who do not use insulin. Simplicity, affordability, insurance eligibility, and integration with primary care workflows influence adoption, particularly among older adults and people managing multiple chronic conditions.

The market opportunity extends beyond device sales to digital coaching, remote review of glucose trends, and practical education that helps users translate readings into sustainable daily habits. USA Diabetes Care Devices By End User• The US home and self-care segment is driven by the shift toward everyday diabetes management outside traditional clinical settings. Patients and caregivers increasingly use connected glucose monitors, smartphone applications, insulin pens, and wearable pumps to make routine treatment decisions and share information with healthcare professionals remotely. Convenience is only one part of the value proposition: discreet wearability, straightforward sensor replacement, clear alerts, accessible interfaces, and reliable supply of test strips, sensors, and infusion sets are equally important. Adoption also depends on whether patients can understand device outputs, manage connectivity problems, and obtain reimbursement or affordable refills. • The US hospital segment is distinguished by the need for clinically reliable glucose monitoring and coordinated diabetes management during acute illness, surgery, intensive care, and other situations in which glucose levels can change rapidly. Hospitals require devices that fit established clinical workflows, support timely intervention, and allow healthcare teams to monitor patients who may be unable to manage their own treatment. Procurement decisions emphasize accuracy, staff usability, infection prevention, documentation, and compatibility with electronic health records and hospital information systems.

Hospitals also play an important role in identifying appropriate technologies, educating patients, and initiating transitions to home-based monitoring or insulin delivery after discharge. • The US diagnostic centers segment focuses on glucose assessment, clinical evaluation, and the identification of patterns that can inform diabetes treatment decisions. These facilities can support device-based assessment through laboratory testing, point-of-care glucose measurements, and professional continuous glucose monitoring, in which a sensor is worn temporarily to reveal glucose trends under normal daily conditions. Unlike home users, diagnostic center patients may rely on clinical staff to apply devices, explain results, and determine whether additional monitoring or treatment adjustments are appropriate. Market opportunities are associated with streamlined testing workflows, dependable equipment, integration with laboratory information systems, and efficient reporting to referring physicians. • The US ambulatory surgical centers segment has specialized requirements because diabetes management must be coordinated with short-stay surgical procedures, anesthesia, fasting, and postoperative recovery. Glucose monitoring devices support the assessment of patients before and after procedures, while insulin delivery decisions must be coordinated with clinical protocols and changes in food intake or medication schedules. Unlike long-term homecare settings, these centers prioritize rapid bedside measurements, dependable performance, simple staff workflows, and clear documentation that supports safe discharge.

Continuous glucose monitoring may provide useful background information for selected patients, but it should not replace required point-of-care testing during surgery.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Diabetes Care Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Blood Glucose Monitoring Systems• Insulin Delivery DevicesBy Disease Type• Type 1 Diabetes• Type 2 DiabetesBy End User• Home/Self-Care• Hospitals• Diagnostic Centers• Ambulatory Surgical Centers.